Volume | 6,382 |
|
|||||
News | - | ||||||
Day High | 8.13 | Low High |
|||||
Day Low | 7.80 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aeterna Zentaris Inc | AEZS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
8.09 | 7.80 | 8.13 | 7.80 | 8.03 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
133 | 6,382 | $ 7.88 | $ 50,303 | - | 1.3601 - 8.3487 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:07:18 | 1 | $ 8.15 | USD |
Aeterna Zentaris Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
37.88M | 4.86M | - | 4.5M | -16.55M | -3.41 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Aeterna Zentaris News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AEZS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.95 | 8.3487 | 1.95 | 3.62 | 27,361 | 5.85 | 300.00% |
1 Month | 2.07 | 8.3487 | 1.95 | 2.74 | 14,714 | 5.73 | 276.81% |
3 Months | 1.87 | 8.3487 | 1.68 | 2.21 | 18,418 | 5.93 | 317.11% |
6 Months | 1.52 | 8.3487 | 1.45 | 2.11 | 15,946 | 6.28 | 413.16% |
1 Year | 3.19 | 8.3487 | 1.3601 | 2.29 | 12,710 | 4.61 | 144.51% |
3 Years | 0.9468 | 8.3487 | 0.1645 | 0.6579878 | 565,055 | 6.85 | 723.83% |
5 Years | 3.60 | 8.3487 | 0.1645 | 1.14 | 1,847,853 | 4.20 | 116.67% |
Aeterna Zentaris Description
AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland. |